Metraipolis › archive › dc_58681ccadeaf

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy — Europe PMC PMID:42358951

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42358951
DOI
10.3389/fimmu.2026.1861537
License (as archived)
solo-consultazione
Archived
2026-10-31T14:55:05.557Z
SHA-256 of the archived text
8c4066c83979d9c9c72f3840108551772831825623214844354fcbbe8ec06df7
Stable URL of this page
https://metraipolis.com/documento/dc_58681ccadeaf

How to cite

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy — Europe PMC PMID:42358951 — Europe PMC (en), https://europepmc.org/article/MED/42358951 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_58681ccadeaf (Metraipolis archive dc_58681ccadeaf, sha256 8c4066c83979d9c9c72f3840108551772831825623214844354fcbbe8ec06df7)
BibTeX
@misc{dc58681ccadeaf,
  title = {Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy — Europe PMC PMID:42358951},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42358951},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_58681ccadeaf; sha256 8c4066c83979d9c9c72f3840108551772831825623214844354fcbbe8ec06df7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358951. Agents can read the archived copy with the MCP tool read_document.